NCT04099563View on ClinicalTrials.gov

Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 14, 2019

Primary Completion Date

November 9, 2019

Study Completion Date

December 9, 2019

Conditions
HEALTHY
Interventions
DRUG

PF-04965842

"For this study, the investigational product is PF-04965842 (provided as 100 mg tablet).~PF-04965842 100 mg tablets will be provided by Pfizer. Investigational product will be presented to the participants in individual dosing containers"

Trial Locations (1)

102200

Beijing Hospital Sub-Center of Beijing Hospital Clinical Trial & Research Center, Beijing

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04099563 - Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants | Biotech Hunter | Biotech Hunter